CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - TUNE IN EVERY DAY AT 4 PM EST!
<< View More Conferences
2015 ASH Annual Meeting and Exposition
Oncology Conference Multimedia
View more videos >>
Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma
Dr. Branagan on Vaccine to Better Protect Myeloma Patients From Flu
Dr. Nguyen on ABL001 in Patients With CML
Oncology Conference Articles
Blinatumomab Shows High CR Rates Across Two ALL Studies
Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.
Response Rates Near 100% for CAR T-cell Therapies in ALL
Two CD19-targeted chimeric antigen receptor-modified T-cell therapies demonstrated complete response rates ranging from 90% to 100% in patients with high-risk acute lymphoblastic leukemia.
No Safety Concerns in Trial of Ibrutinib to Early-Stage CLL
Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.
Next-Generation BTK Inhibitor Taking on Ibrutinib in CLL
Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.
Ibrutinib Bests Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
Ibrutinib Active in Rituximab-Refractory WM
More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.
Pembrolizumab Combo Generates High Response Rate in Refractory Myeloma
The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.
High Response Rates Seen With CAR T-Cell Therapies for NHL
Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.
Adding Rituximab to Chemo Boosts Survival in Subgroup of ALL Patients
Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.
Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML
Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.
Venetoclax Sparks High Response Rate in Poor-Risk CLL Subtype
Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.
Frontline Ibrutinib Significantly Improves Survival in CLL
Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naÃ¯ve elderly patients with chronic lymphocytic leukemia.
Eltrombopag Improves Response Rates in Severe Aplastic Anemia
More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.
Daratumumab Combo Sparks 81% Response Rate in Myeloma
The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory disease that were "rapid, deep, and durable" without introducing any new safety concerns.
Idelalisib Triplet Highly Effective for Relapsed/Refractory CLL
The addition of idelalisib to bendamustine and rituximab (BR) reduced the risk of progression or death by 67% compared with BR alone for patients with relapsed/refractory chronic lymphocytic leukemia.
Oral Ixazomib Triplet Improves PFS in Myeloma
An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Study Suggests Role for CAR Therapy After Transplant in Advanced B-cell Cancers
Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.
CAR T-Cell Infusion Leads to Eradication of Myeloma
Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.
Ruxolitinib Continues to Impress in Long-Term Myelofibrosis Follow-Up
Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.
Ixazomib, Cyclophosphamide Combo Effective for Newly Diagnosed Myeloma
An all-oral triplet therapy of ixazomib, cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma.
Durable Daratumumab Activity Highlighted in Combined Myeloma Analysis
Treatment with the CD38 monoclonal antibody daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.
Benefits of Elotuzumab Sustained in 3-Year Myeloma Data
The combination of elotuzumab, lenalidomide, and dexamethasone showed sustained improvements in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma.
Bortezomib Triplet Therapy New Standard of Care for Untreated Multiple Myeloma
Induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and overall survival compared with lenalidomide and dexamethasone alone for patients with untreated multiple myeloma.
Carfilzomib Bests Bortezomib Across Multiple Myeloma Subgroups
Treatment with carfilzomib reduced the risk of progression or death by 47% compared with bortezomib for patients with relapsed multiple myeloma.
ASH 2015 Preview: Novel Agents, Combinations Abound Across Hematologic Malignancies
In less than 5 years, the treatment landscape for patients with hematologic malignancies has undergone a dramatic transformation, with continued advancements and pivotal data being presented at the 2015 ASH Annual Meeting.
OncLive News Network On Location: In Munich Saturday, October 20
MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC
Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC
Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC
Pembrolizumab/Axitinib Improves Survival in Frontline RCC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.